About Bio-Path
Overview
Leadership
Scientifc Advisory Board
Directors
Partnering Opportunities
Technology
Pipeline
Pipeline
Prexigebersen
BP1001-A
BP1002
BP1003
Patients
Investors
Overview
SEC Filings
Corporate Governance
Media
Press Releases
Events
Presentations & Publications
Careers
Contact Us
Prospectus Supplement (April 2024 ATM)
BPTH_Prospectus-Supplement_20240404_ATM
SEC Form 8-K: Entry into a Material Definitive Agreement.
BPTH_Frm_8-K_20240404
SEC Form 424(b)5: Perspectus Supplement (To Prospectus dated June 14, 2022)
BPTH._424B5_20240327
SEC Form 8-K: Other events, Financial Statements and Exhibits
BPTH-_Form_8-K_20240327
SEC Form 8-K: Entry into Definitive Material Agreement
BPTH_8-K_20240326
SEC Form 8-K: Nasdaq delisting notification
BPTH_Form_8-K_Nasdaq_delisting_notification
SEC Form S-1 Amendment #1 Exhibits only filing
BPTH_S-1_A_2024-03-13
SEC Form 8-K: Regaining Nasdaq Compliance
BPTH_Form_8-K_2024_Nasdaq_Notice_re_Regaining_Compliance
SEC Form 8-K: Press Release dated March 8, 2024
BPTH_-Form-8-K_20240308
SEC Form S-1
BPTH__S-1_20240308
About Bio-Path
Overview
Leadership
Scientifc Advisory Board
Directors
Partnering Opportunities
Technology
Pipeline
Pipeline
Prexigebersen
BP1001-A
BP1002
BP1003
Patients
Investors
Overview
SEC Filings
Corporate Governance
Media
Press Releases
Events
Presentations & Publications
Careers
Contact Us